Previous 10 | Next 10 |
Ted Waller returns to discuss staying bullish but getting more realistic about the cannabis industry. Limited growth rates, margin compression and the need to keep our emotions out of investing. Buying special situations and what stocks are more concerning. For further detai...
Julian Lin returns to discuss two of his favorite cannabis plays - a REIT and an MSO. Cannabis investing philosophy (valuations should drive capital allocations). Net leases, cap rates and how legislation may affect bullish thesis. Smart acquisitions, management compensation, ...
The Green Giants portfolio fared better than the industry benchmarks and is now besting MSOS and YOLO by about 10% year-to-date. New Jersey is the most meaningful new market in 2022 and more stores and bigger grows will add much-needed revenue in the next couple of quarters. In an...
Today, we put small-cap Agrify Corporation in the spotlight for the first time. The company is seeing impressive revenue growth supplying cultivation solutions to the hemp and cannabis industries. A full investment analysis follows in the paragraphs below. For further detail...
Capital is disappearing in the cannabis industry. Mike Regan and Colin Ferrian return to discuss what investors need to understand about valuations (it's not just like tech). Grading California's main players, consumption patterns, price erosion. EBIDA over EBITDA. For a real ...
With Ascend Wellness - and perhaps other MSOs - set to sue the US government, we think it's a good time to hear directly from cannabis executives to get their thoughts on the industry. We hear from TerrAscend's Jason Wild, Ascend Wellness' Abner Kurtin, MariMed's Bob Fireman and Weedm...
We can't control the markets. Investors need patience, more institutional capital and more catalysts, but mostly patience. Matt Hawkins returns to discuss StateHouse/Harborside, the California cannabis market and the developing US picture. Advice to retail investors and why managi...
ETFs have been a way to manage volatility and uncertainty in the cannabis sector. Performance comparison of the ETFs vs. individual stocks. Many investors can now move away from the ETFs and focus more on specific companies. For further details see: A Reassessment Of The...
NewLake Capital Partners is a small copycat REIT, modeled closely on Innovative Industrial Products. NLCP's price performance since inception has been pretty much all downhill. NLCP's returns YTD, along with those of other Cannabis REITs, are underperforming even the struggling RE...
Capital is disappearing in the cannabis industry. Mike Regan and Colin Ferrian return and we discuss what investors need to understand about valuations (it's not just like tech). Grading California's main players, consumption patterns, price erosion. EBIDA over EBITDA. For a r...
News, Short Squeeze, Breakout and More Instantly...
Amplify ETF Trust - Amplify Seymour Cannabis ETF Company Name:
CNBS Stock Symbol:
NYSE Market:
2024-01-19 07:30:51 ET The Leading Cannabis ETFs to Consider in 2024 Cannabis ETFs are garnering attention in 2024 as the industry shows promising growth. Key players like MJ, MSOS, and CNBS dominate this sector. These ETFs offer diversified exposure to cannabis-related stocks. This...
2023-10-27 07:30:02 ET Q4 2023’s Cannabis ETF Leaders: Where to Invest The cannabis sector continues to entice investors with its prospects for expansion and financial success as we take on the last quarter of 2023. Cannabis Exchange-Traded Funds (ETFs) have become popular for in...
2023-09-15 07:30:42 ET Top Marijuana ETFs for September 2023 In 2023, the cannabis industry and top marijuana stocks are blazing a trail of exponential growth, presenting investors with a unique opportunity to tap into this flourishing sector. As regulatory landscapes evolve and soc...